Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $38.5M | $220M | $270M | $423M | $678M |
| Revenue growth | — | — | — | — | — | 471.2% | 22.7% | 56.6% | 60.1% |
| Operating income | -$65.4M | -$108M | -$170M | -$157M | -$157M | $9.77M | -$25.2M | -$45.6M | $77.2M |
| Operating margin | — | — | — | — | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Net income | -$64.9M | -$103M | -$162M | -$161M | -$158M | $183M | $14.1M | -$43.2M | $59.0M |
| Net margin | — | — | — | — | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (diluted) | -$35.85 | -$3.49 | -$2.99 | -$2.61 | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50.2M | -$81.0M | -$158M | -$137M | -$126M | $5.81M | $13.3M | $25.7M | $138M |
| Capital expenditures | $69.0K | $5.29M | $3.20M | $283K | $415K | $105K | $130K | $277K | $1.57M |
| Free cash flow | -$50.3M | -$86.3M | -$162M | -$137M | -$127M | $5.70M | $13.2M | $25.4M | $136M |
| Dividends paid | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $45.6M | $72.0M | $46.9M | $114M | $122M | $123M | $108M | $184M | $166M |
| Total assets | $47.5M | $322M | $255M | $349M | $233M | $460M | $526M | $581M | $764M |
| Total liabilities | $17.4M | $42.7M | $29.1M | $37.5M | $47.8M | $63.5M | $87.5M | $142M | $196M |
| Shareholders' equity | -$89.7M | $279M | $225M | $312M | $185M | $396M | $439M | $438M | $568M |
| Retained earnings | -$91.0M | -$194M | -$356M | -$517M | -$675M | -$492M | -$478M | -$521M | -$462M |
| Shares (wtd avg diluted) | — | — | 54.0M | 61.8M | 68.6M | 70.4M | 71.9M | 71.4M | 79.0M |
Every figure is extracted from Kiniksa Pharmaceuticals International, plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.